LAWRENCE, Mass., Aug. 4, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, joins over one hundred NxStage patients in celebrating their ten-year anniversary on home hemodialysis with the NxStage® System One™.
"The number of personal goals I've achieved over the past 10 years would not have been possible without the NxStage System One," said Jenna Smith, a NxStage patient for 13 years. "I'm extremely thankful to have found home hemodialysis because my treatment fits into my life whenever and wherever I want, instead of the other way around."
The NxStage System One is the first and only truly portable hemodialysis system cleared in the United States for home hemodialysis and home nocturnal hemodialysis. Its simple and portable design provides a range of hemodialysis therapy options including more frequent treatments at home during the daytime or at night, while sleeping.
More frequent home hemodialysis is associated with clinical benefits and improved outcomes, including a 13% lower risk of death compared to traditional in-center hemodialysis1, and an 11% reduction in left ventricular hypertrophy, reducing stress on the heart.2,3 More frequent home hemodialysis is also linked to an 87% improvement in recovery time after treatment.4
"A little over a decade ago, NxStage introduced a revolutionary dialysis machine, the System One, to give patients the freedom and flexibility to do their dialysis when and where they wanted. It's incredibly rewarding to join over one hundred of our patients in celebrating their ten plus year anniversary on HHD," said Jeff Burbank, Founder and CEO of NxStage Medical, Inc. "This milestone is a testament to both the strength of our patients and the life changing benefits of our therapy."
The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent hemodialysis using the NxStage System One. Additionally, the reported benefits of home and/or more frequent hemodialysis may not be experienced by all patients. Patients and providers are encouraged to contact their state regulators to discuss state-specific regulations that may impact dialysis in the skilled nursing facility setting.
About the NxStage System One The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. The simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on-site on-demand. Unlike conventional hemodialysis systems, the System One family of products requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health® platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals, dialysis centers and skilled nursing facilities. Its safety and performance have been demonstrated by experience with more than 14 million treatments with over 30 thousand patients around the world. www.nxstage.com.
About NxStage Medical NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
1. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol. 2012;33(5):895-904. 2. FHN Trial Group. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300. 3. Culleton BF, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759-2767. 4. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis on depressive symptoms and post dialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.